News

Dr. Taylor recently discussed organ-on-a-chip technology and the Pitt-TraCe qualification program on the Behind Our Science podcast. – July 30, 2025 Episode 29- Organ-on-a-Chip: an afternoon with Dr. Lans Taylor

A letter of intent for the LAMPS as a DDT to establish the hepatotoxicity of drug candidates in patients with MASLD and assist in the determination of drug candidate dosing in clinical trials when patients with MASLD are included has been submitted and determined to be reviewable by the CDER ISTAND pilot program for qualification. […]

The letter of intent for the LAMPS as a DDT to establish the hepatic clearance of drug candidates in patients with MASLD and assist in the determination of drug candidate dosing in clinical trials when patients with MASLD are included has been accepted into the CDER ISTAND pilot program for qualification. – June 23, 2025.

Dr. Mark Miedel presented Patient-specific Microphysiology Systems as an Innovative Precision Medicine Platform for Metabolic-Dysfunction Associated Steatotic Liver Disease at the 23rd NIH MPS World Summit being held in Seattle, WA June 9-14, 2024

Dr. Mark Schurdak presented Qualification of Patient-derived Biomimetic Liver MPS as Drug Development Tools for Drug Metabolism, Toxicity, Drug Efficacy Testing, and Clinical Trial Cohort Selection  at the 23rd NIH MPS World Summit being held in Seattle, Washington June 9-14, 2024

Mengying (Summer) Xia presented a poster Toward Precision Medicine for Metabolic Dysfunction-Associated Steatotic Liver Disease Comparing Wildtype and a High-Risk PNPLA3 Variant in a Human Biomimetic Liver Microphysiology System at the 23rd NIH MPS World Summit being held in Seattle, Washington June 9-14, 2024

Dr. Mark Schurdak presented a talk “’Show Me the Reproducibility!’ Data Management Best Practices to Enhance Confidence in Complex MPS Models and Their Predictions” at the Society of Toxicology Annual Meeting held in Salt Lake City, Utah March 10-14, 2024.